Business Context and Reporting Period
This Form 8-K Current Report was filed by Nemus Bioscience, Inc. (not Skye Bioscience, Inc.) on February 5, 2016. The filing discloses the entry into a material definitive agreement with Albany Molecular Research Inc. (AMRI) to support the development of Nemus's prodrug of tetrahydrocannabinol (THC).
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It details specific estimated costs associated with the new agreement:
- Process Development Fees: Estimated between $154,000 and $183,000 for initial evaluation and development.
- Analytical Method Development Fees: Estimated at $142,900.
- Additional Costs: Potential fees for sample production, stability studies, and project extensions are not quantified in this filing.
Material Changes
The primary material change is the execution of a letter agreement with AMRI. This agreement establishes a framework for process development, analytical method qualification, sample production, and stability studies for Nemus's THC prodrug. The filing does not report changes to prior period financial results.
Outlook, Risks, and Contingencies
Management Commentary and Terms:
- Termination Rights: Nemus may cancel or delay projects prior to the start date but must reimburse AMRI for incurred costs and reasonable foreseeable costs, including lost revenue from reserved facilities.
- General Termination: Nemus may terminate the agreement in whole or part with 30 days' written notice.
- Default Provisions: Either party may terminate for uncured defaults, including insolvency, bankruptcy, or material non-compliance.
- Contingencies: If manufacturing steps fail or result in deviations through no fault of AMRI, the parties must agree on supplemental proposals for additional fees.
Investor Verification Checklist
- Verify the total cash impact of the $154,000 to $183,000 process development fee and the $142,900 analytical fee against current liquidity.
- Confirm the status of the THC prodrug development pipeline and the necessity of AMRI's services.
- Review the potential liability for "reasonable and foreseeable costs" and lost revenue if Nemus cancels the project.
- Monitor for future filings regarding the actual costs of sample production and stability studies, which are currently undefined.